



Article scientifique

Article

2021

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience - a study in exceptional aging

Treyer, Valerie; Meyer, Rafael S; Buchmann, Andreas; Crameri, Giovanni A G; Studer, Sandro; Saake, Antje; Gruber, Esmeralda; Unschuld, Paul; Nitsch, Roger M; Hock, Christoph; Gietl, Anton F

How to cite

TREYER, Valerie et al. Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience - a study in exceptional aging. In: PloS one, 2021, vol. 16, n° 2, p. e0247225. doi: 10.1371/journal.pone.0247225

This publication URL: <https://archive-ouverte.unige.ch/unige:161263>

Publication DOI: [10.1371/journal.pone.0247225](https://doi.org/10.1371/journal.pone.0247225)

RESEARCH ARTICLE

Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience—a study in exceptional aging

Valerie Treyer^{1,2*}, Rafael S. Meyer¹, Andreas Buchmann¹, Giovanni A. G. Cramer¹, Sandro Studer¹, Antje Saake¹, Esmeralda Gruber¹, Paul G. Unschuld^{1,3#}, Roger M. Nitsch^{1,4}, Christoph Hock^{1,4}, Anton F. Gietl¹

1 Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland, **2** Department of Nuclear Medicine, University Hospital of Zurich, University of Zurich, Zurich, Switzerland, **3** Hospital for Psychogeriatric Medicine, Psychiatric University Hospital Zurich, Zurich, Switzerland, **4** Neurimmune, Schlieren-Zurich, Switzerland

Current address: Psychogeriatric Medicine, Department of Psychiatry, Geneva University Hospitals (HUG), Geneva, Switzerland

* Valerie.treyer@usz.ch



OPEN ACCESS

Citation: Treyer V, Meyer RS, Buchmann A, Cramer GAG, Studer S, Saake A, et al. (2021) Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience—a study in exceptional aging. *PLoS ONE* 16(2): e0247225. <https://doi.org/10.1371/journal.pone.0247225>

Editor: Stephen D. Ginsberg, Nathan S Kline Institute, UNITED STATES

Received: May 19, 2020

Accepted: February 3, 2021

Published: February 19, 2021

Copyright: © 2021 Treyer et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript.

Funding: This study was supported by ZInEP, The Zurich Program for Sustainable Development of Mental Health Services, Maxi Foundation, GE Healthcare (IIS ID #270 and 114-2014-IIR-0076) and institutional support from the Institute for Regenerative Medicine (IREM), University of Zurich, Switzerland. Funds were requested by CH, AGF and VT. The funders had no role in study

Abstract

Background

Exceptional agers (85+ years) are characterized by preserved cognition presumably due to high cognitive reserve. In the current study, we examined whether personality, risk and protective factors for dementia as well as quality of life are associated with core features of Alzheimer's disease (amyloid-deposition and hippocampal volume) as well as cognition in exceptional aging.

Methods

We studied 49 exceptional agers (average 87.8 years, range 84–94 years), with preserved activities of daily living and absence of dementia. All participants received a detailed clinical and neuropsychological examination. We used established questionnaires to measure lifetime experience, personality, recent physical and cognitive activity as well as quality of life. Cerebral amyloid-deposition was estimated by 18-[F]-Flutemetamol-PET and manual hippocampal volumetry was performed on 3D T1 MRI images.

Results

In this sample of exceptional agers with preserved activities of daily living, we found intact cognitive performance in the subjects with the highest amyloid-load in the brain, but a lower quality of life with respect to autonomy as well as higher neuroticism. Higher self-reported physical activity in the last twelve months went with a lower amyloid load. Higher self-reported leisure-time/ not work-related activity went with better executive functioning at older age.

design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Valerie Treyer, Rafael S. Meyer, Andreas Buchmann, Giovanni A. G. Cramer, Sandro Studer, Antje Saake, Esmeralda Gruber, Paul G. Unschuld and Anton F. Gietl have nothing to disclose with respect to this publication. Since August 2018, Christoph Hock has assumed the role of Chief Medical Officer at Neurimmune AG, Schlieren, a spin-out of the University of Zurich, and Roger Nitsch has assumed the role of Chief Executive Officer of Neurimmune AG. Both Christoph Hock and Roger Nitsch are co-founders and board members of Neurimmune AG. Neurimmune AG develops therapeutic strategies against Alzheimer's disease. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Conclusion

Even in exceptional aging, high amyloid load may subtly influence personality and quality of life. Our findings support a close relationship between high physical activity and low amyloid-deposition and underscore the importance of extracurricular activities for executive functions. As executive functions are known to be a central resource for everyday functioning in fostering extracurricular activities may be effective in delaying the onset of dementia.

Introduction

According to the WHO, life expectancy at birth in Europe increased from 72.0 years in 2000 to 77.5 years in 2016, with a healthy life expectancy at birth of 68.4 years. As age is the most important risk factor for dementia, this was paralleled by a rising number of patients with dementia worldwide (50 million of people with dementia in 2019 [1]). Interestingly, recent epidemiological studies showed that age-specific incidence of dementia decreased by 24% from 1990 to 2000 in high-income countries supposedly due to beneficial changes in modifiable risk factors like higher education and reduction of vascular risk factors [2, 3].

Pathologies accumulating with higher age are beta-amyloid deposits and neurofibrillary tangles containing misfolded Tau protein, the typical hallmarks of Alzheimer's disease. Also cerebrovascular brain lesions and other additional protein aggregates like TDP43 or alpha-synuclein become increasingly prevalent with age, and could exert a synergistic detrimental impact on the brain [4–7]. Recent developments in brain imaging brought the possibility to visualize certain pathologies. By using positron emission tomography with dedicated radiopharmaceuticals we can measure amyloid- and tau accumulation in the brain [8–13]. Amyloid-pathology accumulates in the brain over decades before first cognitive symptoms of Alzheimer's disease occur [8, 14]. Over time the decrease in brain tissue especially in medial-temporal regions can be measured as a consequence of disease progression already in a pre-clinical/presymptomatic stage [15–19]. However, atrophy in the medial-temporal region is not specific to Alzheimer's disease but occurs in various other neurodegenerative diseases, and up to a certain degree also in normal aging [15, 20, 21]. Volume losses may be associated with cognitive impairment [15, 20–22]. In a population older than 85 years the limbic predominant age-related TDP-43 encephalopathy (LATE) is frequently detectable, but due to lacking in vivo diagnostics for humans it can only be diagnosed post mortem [7].

Populations of exceptional agers offer a unique possibility to identify factors that moderate the link between pathology and cognition [23–27]. Here the concept of cognitive reserve is of high relevance. Cognitive reserve is regarded as the collection of factors that counteract the impact of accumulation of cerebral pathologies and preserve a subject's cognitive functions [28–31]. To investigate the moderating influence of cognitive reserve, we examined a population of subjects of 85 years and older without evidence for dementia and intact activities of daily living. The central research question was whether established risk- and protective factors for clinical dementia are also associated with biomarkers of Alzheimer's disease pathology and cognitive functioning in a sample of exceptional agers. Previous studies have shown relationships between dementia incidence and protective factors like cognitive and physical activities [32–36], lifetime experience [20, 37–40], or personality traits [41–44] but findings were equivocal. Higher physical activity was associated with lower brain amyloid uptake in Apolipoprotein E (ApoE) ϵ 4 carriers and in participants with better cognitive performance [45–47], but other studies did not find this relationship (for example, ref [48]). In this study, cognitive

functions of older adults (70–89 years old) did not benefit from a two years physical activity program [48]. Another trial showed, that aerobic exercise training increased hippocampal volume compared to a measurable decline in the control group [49].

Positive effects of lifetime experiences (e.g. education, occupational complexity, extracurricular / leisure time activities) have been postulated due to observations, that these factors are related to less hippocampal atrophy [20, 39], higher cognitive reserve in late-life [50] as well as fewer white matter lesions and less amyloid- deposition [51]. Education seems to moderate associations between pathologies and cognition [52] but may not directly contribute to pathology [53]. Cardiovascular risk factors like physical inactivity, unhealthy diets, smoking, obesity and hypertension are modifiable and thus may serve as targets for dementia prevention strategies [54–56]. The impact of these factors on dementia, diabetes and cardiovascular events depend on genetic and other external factors [57–59]. It was repeatedly demonstrated that multifactorial interventions to modify risk factors are useful to prevent neurodegeneration and dementia [60–63].

The concept of exceptional aging provides a framework to understand compensation or protective mechanisms in healthy aging despite the accumulation of various pathologies, while the study of younger currently non-demented cohorts will necessarily include subjects towards pathways of non-successful and successful aging [64–66].

We believe that a thorough investigation of such a population could provide important insights for disease prevention strategies. To add to this picture the design of our study, aims to address important risk factors and their relationship to amyloid deposition and hippocampal volume as biomarkers of brain pathology, and cognition. Risk factors of interest in our study are life experiences, cognitive and physical activity. These were complemented with measures for quality of life and subjective memory complaints as possible subtle consequences of Alzheimer's pathology as these factors were associated with Alzheimer pathology biomarkers in younger cognitively healthy populations [67–70]. Furthermore we studied personality traits as they could either be a risk factor for Alzheimer's dementia or directly influenced by Alzheimer's pathology [41–43, 71].

Materials and methods

49 older adults (mean age 87.8 year (SD 3.0y)), recruited via advertisement or direct mailing, participated in this study. Parts of this data set have been published previously, comparing a part of the present sample with younger-old subjects with respect to plaque and iron load, entorhinal cortex volume and white matter hyperintensities [72]. The oldest participant was 94 years at baseline and the youngest subject was enrolled 3.5 months before his 85th birthday.

The clinical work-up included assessment of medical history (in particular, prior episodes of brain disease, e.g. ischemia, trauma) and familial history for neurodegenerative diseases, psychiatric, neurological, and internal medicine status. Furthermore ECG and routine laboratory testing, Mini Mental Status Examination (MMSE) [73], Instrumental Activities of Daily Living Scale (IADL) [74] and Hamilton Rating Scale for Depression [75] as well as ApoE genotyping were performed in all patients.

Main inclusion criteria were age of 85 or older and preserved everyday functioning. Main exclusion criteria were clinical dementia as assessed by clinical evaluation or significant neurological, psychiatric or other diseases that may influence cognition or may interfere with the participant's ability to give informed consent or with compliance at the visits. The study was conducted in accordance with the local law, the Declaration of Helsinki [76] and approved by the ethics committee of the canton Zurich.

Neuropsychology and domain-specific indices

Standard neuropsychological, psychiatric and neurological assessments were performed. The rationale for test selection was to complement standard dementia tests with tests with a higher cognitive load for each cognitive domain.

After a short informal interview to assess subjective cognitive complaints and factors with possible influence on the test results (e.g., education, alcohol consumption and medication, recent long-distance travel over multiple time zones) as well as characteristics of free language expression, the following neuropsychological tests were administered in the same order: the German version of the CERAD battery [77]; phonematic fluency over three minutes (letters) [78]; the German version of the RAVLT (VLMT; [79]); the Rey-Osterrieth Complex Figure ([80]; including immediate and late recall, evaluated with Taylor's criteria, [81]); Digit span and Corsi block task (each forward and backward, as in WMS-R; [82]), nonverbal fluency test (5-point test [83]) and Tower of London [84].

All individual test results were z-transformed based on age- and partially years of education corrected clinical norms. The composite scores were generated by averaging all individual transformed test scores relevant for the respective domain. The episodic memory score included the subscores learning, recall and recognition based on VLMT task for learning and recognition, and CERAD's word learning, VLMT late recall and figures recall from the CERAD battery. The working memory score consisted of Digit span and Corsi block backward. The visuospatial construction score equals the Rey Figure copy, and the naming score equals the short version of the Boston naming test. The executive score included the subscores fluency (verbal and nonverbal fluency tests), non-fluency (colour-word interference and set switching) and error control (based on the sum of errors in three different tests: phonematic fluency, Stroop and Tower of London). The error control scores was a sum of the z-scores and multiplied with (-1) to get higher values for better performances.

Questionnaire-based scales

For the lifetime experience questionnaire, the same weight scores for the sub-items were used as in an Australian cohort (appendix C of the original publication) [85]. The questionnaire covers three stages of aging, Young Adulthood from 13 to 30 years covering the educational and self-identity finding and first career stage. Mid-life from 30–64 years is characterized by a focus on work-life balance, maintenance of relationships and growing importance of caregiving for children or parents. Late life starts at age of 65 years where many people are retiring and have to reorient their activities beyond work. The questions for each life stage comprise two sets. The first consists of questions on education and work-related activities and the second consisted of general questions about leisure, physical and social activities. We labeled those as 'extracurricular activities', as they are not directly related to work or education. Sample questions for these activities are how often participants played or practiced a musical instrument, did artistic pastime, sports or other physical activities, how often they met with friends or family, how often they read, whether they spoke a second language or how far they have travelled across continents.

The WHOQOL-OLD questionnaire in its original German version by the WHO was used to assess quality of life (QOL) in the six domains: sensory abilities, autonomy, past, present and future activities, social participation, death and dying as well as intimacy [86]. The questionnaire consists of 24 questions answered on a 5-point scale. The questions assess QOL over the last two weeks. Sample Questions for the six domains are: "To what extent do impairments to your senses (e.g., hearing, vision, taste, smell, touch) affect your daily life?", "How much freedom do you have to make your own decisions?" "How much do you feel that you have

received the recognition you deserve in life?”, “How satisfied are you with the way you use your time?”, “How scared are you of dying?”, “To what extent do you experience love in your life?”.

To assess current cognitive and physical activities over the last 12 months, a standardized questionnaire was used as described in the original publication [32]. The questionnaire assesses ten cognitive activities like reading, playing games and music, arts and crafting activities as well as social activities were measured. Watching TV for a certain amount of hours did not count for the final cognitive score. In addition the questionnaire covers six physical activities, namely light activities like laundry, vacuuming and light exercises like walking; moderate activities and exercise like gardening or aerobics and strength training as well as information on heavy activities and vigorous exercises like heavy digging, or tennis and jogging. All activities were weighted according frequency of performance of once a month or less (0 points), 2–3 times per month (0.5), 1–2 times per week (1.5), 3–4 times per week (3.5), 5–6 times per week (5.5) and 7 points for daily activities. For cognitive activities a maximum of 70 and for physical activities a maximum of 42 could be reached.

The NEO-FFI was applied to assess the five personality domains, with a particular interest neuroticism as its probable relationship with healthy aging and Alzheimer’s-related pathology [87].

Subjective cognitive complaints were assessed according to Schmand et al.,1996 [70]. This questionnaire consists of 10 items on memory complaints. Example questions are whether other people found the participants forgetful and how often they forgot things, became confused or had concentration problems.

Imaging based Alzheimer’s diseases biomarkers

All participants received a standard dynamic PET/MR (Signa PET/MR GE Healthcare) scan with approx. 140MBq of 18[F]-Flutemetamol. A BRAVO 3D T1MRI sequence with voxel size 1mm (8-channel coil) was acquired in parallel to calculate cortical beta-amyloid SUVR with bilateral cerebellar grey matter reference for the PET data analysis, which was conducted with the PMOD NeuroTool 3.6 (PMOD Technologies LLC., Switzerland).

To minimize white matter spillover signal and to reduce partial volume effects from cerebrospinal fluid in grey matter regions of interest in the PET data, MRI images were segmented with 3 probability maps. Cortical regions of interest were defined according to Hammer’s maximum probability atlas. Deep nuclei parcellation was performed with NeuroTool (knowledge based, with 20 reference sets). The cut-off for grey matter–white matter segmentation was selected at 50% probability. Automatic outlining of the regions of interest was evaluated by an expert (VT) in each individual scan and corrected manually in PMOD if necessary. Late phase uptake values were calculated as average late frames activity (85 to 100 minutes post injection). The region of interest estimating cortical amyloid-load was defined as the average of cortical Hammer’s atlas defined regions that are overlapping with centiloid regions definition [88] thus not including regions in mediotemporal, occipital, central structures as well as pre- and postcentral gyrus.

A higher-resolution 3D T1 FSPGR (IR600, voxel size 0.5mm) image scanned on a 750W 3T (32-channel coil)-scanner was used for manual outlining of hippocampal volume by an expert (AB).

Volumes were outlined using MRICroN on the coronal slices of the 3D images (with the axial and sagittal views open to verify). The most posterior slice of the anterior hippocampus was outlined as the last (most posterior) slice where the upper part (‘cover’) of the hippocampus goes as far medial as the lower part in an unbroken sheet of grey matter (before the ‘snail’-

shape starts; within-structure landmark). Each hippocampus was outlined in an anterior-to-posterior fashion. Fimbria and fornix were excluded. Dark holes were cut out if they were wider than the size of the pen. Volumes in cm^3 were divided by whole brain volume as derived from SPM 8 VBM (fil.ion.ucl.ac.uk/spm) and results were multiplied by 10'000 for readability. Total hippocampal volume was calculated as averaged sum of the left and right anterior plus posterior hippocampal volumes.

Statistics

Statistical analysis was done with SPSS 25 (IBM). As this is an exploratory study, all p-values are reported uncorrected. The number of analyses done for each research question is provided in the result sections. SUVR values were used in the analyses as continuous variable or as quartile groups. Median cortical SUVR values were 1.41 (IQR 0.3) (mean 1.56, SD 0.48) and ranges based on quartiles were as follows: Q1 = 1.09–1.29, Q2 = 1.29–1.40, Q3 = 1.40–1.60, Q4 = 1.60–3.2.

Nonparametric testing was performed wherever assumptions for parametric testing (Gaussian distribution as assessed by Kolmogorov-Smirnov test) were not met, which was the case in the majority of variables. In supplemental [S1 Table](#) we listed all continuous variables with the results of the Kolmogorov-Smirnov test. To include potential confounders we used partial regression or general linear modelling to explore the effects of potential confounders. The continuous variables were transformed by replacing outliers with cutoff values (standard deviation >3) and rescaled them with a Box-Cox transformation to mean 0 and standard deviation 1 as implemented in SPSS.

Spearman's tests were used for the primary correlational analyses without adjustment for age, sex and education. Significant correlations were additionally tested with partial correlations with the respective covariates age, sex and education using the Box-Cox transformed continuous variables.

In a similar vein, group comparisons were calculated with Kruskal-Wallis tests (3 or more categories) or Mann-Whitney U tests (2 categories); significant comparisons were explored further with the respective general linear modelling methods including the covariates age, sex and education using the Box-Cox transformed variables.

ApoE 4 Genotype was not included in the analyses due to the low number of $\epsilon 4$ carriers (6) half of which had the combination $\epsilon 2/\epsilon 4$.

All tests were performed two-sided.

Power analysis for correlations was calculated using the final sample size $N = 49$ and type I error of 0.05. With the program G*power the post-hoc power calculation for correlation analysis was used testing against an H_0 hypothesis of a $\rho = 0$ [[89](#)].

Results

Description of study population

[Table 1](#) summarizes demographic and clinical parameters of the study population. The IADL includes the actual points of subject scores irrespective whether a task was never performed in lifetime or could not be performed due to other reasons, e.g., physical incapacity. [Fig 1](#) shows a horizontal section of an 18[-F]-Flutemetamol scan indicative of high amyloid load (A) and with low amyloid load (B) as well as the distribution of cortical SUVR values in the study population.

Whole brain volume corrected hippocampal volumes (left plus right side) were on average 9.5 (SD 1.46) with a range of 7.6 to 15.33.

No correlations were detectable between cerebral amyloid-load and hippocampal volume.

Table 1. Overview on study sample.

	Mean (SD) or number (%)
Age	87.8 years (2.99)
sex (female/male)	15 / 34 (30.6% / 69.4%)
Education	14.12 years (2.9)
Education by sex (female/male)	12.87 (2.2) / 14.68 (3.0)
BMI	25.6 (3.2)
Hamilton score	1.35 (2.1)
MMSE	28.35 (1.8)
IADL items	7.33 (1.6)
living on their own alone	26 (53.1%)
living at home with partner	20 (40.8%)
living in dedicated home for older adults	3 (6.1%)
nursing support at home	3 (6.1%)
domestic help/ cleaner used	30 (61.2%)
active driving	29 (59.2%)
ApoE $\epsilon 3/\epsilon 3$	34 (69.4%)
$\epsilon 2/\epsilon 3$	9 (18.4%)
$\epsilon 3/\epsilon 4$	3 (6.1%)
$\epsilon 2/\epsilon 4$	3 (6.1%)
Risk factors and cardiovascular disease	
self-reported cognitive reduction noted (only 3 confirmed by relatives)	23 (46.9%)
sleeping problems	13 (26.5%)
current smokers (2 only pipes)	3 (6.1%)
never smoked	22 (44.9%)
smoked in the past	24 (49%)
alcohol <80ml	43 (87.8%)
alcohol >80ml	1 (2%)
no alcohol	5 (10.2%)
arterial hypertension	39 (79.6%)
Diabetes	4 (8.2%)
Hypercholesterinaemia	20 (40.8%)
history of myocardial infarction	9 (18.4%)
first grade relatives with dementia	5 (10.2%)

Data is presented as mean and standard deviation or number of cases and percentages of the total study population.

<https://doi.org/10.1371/journal.pone.0247225.t001>

Sex and age effects

Women and men did not differ in age, whole brain volume corrected hippocampal volume and amyloid-load. Compared to men, women had fewer years of education (Mann-Whitney $U = 370.5$, $p = 0.011$) and less total lifetime experience in midlife (Mann-Whitney $U = 367.5$, $p = 0.014$), especially in job-related categories (Mann-Whitney $U = 464$, $p = 0.001$). No differences were seen in the neuropsychological composite score except for episodic memory recall score where women scored better (Mann-Whitney $U = 139$, $p = 0.032$).

Neither cerebral amyloid-load nor hippocampal volume correlated with age. In addition, no neuropsychological performance variable correlated with age (note that z-values were partially age-corrected and age range was limited in this study).




Fig 1. Example Images and distribution of amyloid SUVR. A: Example of a participant with amyloid SUVR = 3.2, age = 86, MMSE = 29 and ApoE = $\epsilon 3/\epsilon 3$. The 4mm Gaussian filtered image displays SUVR is scaled from 0–4.5 SUVR. B: example of a participant with amyloid SUVR = 1.2, age = 86, MMSE = 29 and ApoE = $\epsilon 3/\epsilon 3$. The SUVR image is scaled from 0–3.5 SUVR. C: histogram of cortical amyloid SUVR (reference region was bilateral cerebellar grey matter).

<https://doi.org/10.1371/journal.pone.0247225.g001>

Cognitive performance—no association with imaging biomarkers

MMSE score did not correlate with corrected hippocampal volume nor with amyloid-load. Neuropsychological test performance did not correlate with amyloid-load in any of the cognitive domains.

One significant and negative correlation between cognitive composite scores and hippocampal volume was identified with the recognition score (Spearman's $\rho = -0.297$, $p = 0.042$). The partial correlation using transformed variables and with covariates age, sex and education the correlation remained was significant ($r = -0.317$, $p = 0.036$, $df = 42$).

Table 2 lists the values of the composite scores overall and for the groups representing first and fourth quartile of amyloid deposition. None of the differences were significant (Mann-Whitney U: $p > 0.25$). As some participants did not perform all tasks the number of datasets is indicated next to the composite scores in brackets.

We used the subjective memory questionnaire [70] to assess memory complaints in a standardized manner. 19 (38.8%) participants stated no memory complaints, 29 (59%) stated complaints without resulting daily life problems. Only one subject stated memory complaints with resulting problems. The overall test score was low (total score of 2.1; SD 1.5). There was no

Table 2. Neuropsychological assessment results.

Composite Scores for Domains (N completed)	All subjects mean (SD)	Q1 Amyloid load	Q4 Amyloid load	ε2/ε3 or ε3/ε3	ε2/ε4 or ε3/ε4
Working Memory score (48)	-0.30 (0.9)	-0.11 (0.9)	-0.43 (1.0)	-0.35 (0.8)	0.11 (1.1)
Learning score (47)	-0.05 (0.8)	-0.02 (0.7)	-0.15 (1.0)	-0.10 (0.8)	0.33 (0.8)
Recall score (47)	-0.18 (0.9)	-0.13 (0.8)	-0.07 (1.0)	-0.30 (0.9)	0.61 (0.7)
Recognition score (47)	-0.47 (1.2)	-0.64 (1.1)	-0.52 (1.4)	-0.53 (1.2)	-0.07 (1.1)
Executive Functions score (44)	0.07 (0.5)	0.03 (0.4)	-0.06 (0.5)	0.04 (0.5)	0.30 (0.4)
Fluencies subscore (46)	-0.01 (0.7)	-0.08 (0.7)	-0.19 (0.6)	-0.02 (0.7)	0.08 (0.6)
Not Fluencies subscore (46)	0.21 (0.6)	0.30 (0.4)	0.14 (0.5)	0.19 (0.6)	0.39 (0.3)
Error Control subscore (45)	-1.02 (1.0)	-0.80 (0.8)	-1.50 (1.4)	-1.07 (1.0)	-0.67 (0.5)
Visuo Construction score (47)	-0.14 (0.9)	-0.11 (1.3)	0.01 (0.8)	-0.07 (0.8)	-0.69 (1.7)
Naming score (48)	0.60 (1.1)	0.66 (1.1)	0.52 (1.4)	0.50 (1.1)	1.30 (0.8)

Z-scores of the composites derived from the neuropsychological examination. Executive functions score is split in three sub scores. The first column lists total average scores with standard deviation in parentheses, the next two columns list the scores of the participants with lowest and highest amyloid load (quartile 1 and quartile 4 of cortical amyloid SUVR). No differences in cognitive functions were observed with respect to amyloid load ($p > 0.25$ Mann-Whitney U Test). Also ε4 carrier and non-carriers were grouped in the last two columns. The respective neuropsychological Z-score values are presented. As there were only 6 ε4 carriers the averages need to be interpreted with care and no statistical comparisons were performed due to this imbalance. Z-scores in bold indicate values higher/better than total average of the sample.

<https://doi.org/10.1371/journal.pone.0247225.t002>

correlation of the total score with amyloid-load (SUVR), hippocampal volumes or cognitive tests (12 correlations were performed).

Highest amyloid load is associated with lower experience of autonomy

Our participants had a total quality of life score of 93.9 (ranging from 63–115, SD 11.3) considering the possible scoring range of 24–120 of the WHOQOL-OLD [86].

The average and standard deviation values of the sub scores are listed in Table 3.

With respect to the relationship with amyloid the QOL aspect autonomy showed a significant difference between the 4 quartiles of amyloid-load (Kruskal-Wallis 7.9, $p = 0.047$). Visually the highest amyloid SUVR subgroup showed lower values than the other groups. But the post hoc Mann-Whitney U comparison between Q4 and Q1-3 did not show significance ($U = 145.5$, $p = 0.072$). A total of 7 comparisons were made.

In Table 3 the QOL values for the first and fourth quartile are displayed. Over all facets, the average value of the participants in the group with highest amyloid load was lower than the values from the group with lowest amyloid load. None of the direct comparisons between subgroups quartile 1 versus quartile 4 reached significance (Mann-Whitney-U $p > 0.16$).

Table 3. Results of WHOQOL-OLD split by amyloid load and with reference values.

WHOQOL-OLD Facets	Study Sample	Q1 Amyloid load	Q4 Amyloid load
	mean (SD)	mean (SD)	mean (SD)
Sensory Abilities	15.00 (3.27)	16.42 (2.71)	13.83 (4.04)
Autonomy	16.49 (2.39)	16.42 (2.50)	15.25 (2.99)
Past, Present and Future activities	16.02 (2.11)	16.25 (2.22)	15.67 (2.06)
Social Participation	15.39 (2.58)	14.67 (2.31)	14.92 (3.09)
Death and Dying	15.35 (3.69)	16.17 (3.41)	15.17 (3.86)
Intimacy	15.69 (3.30)	15.42 (4.12)	13.92 (3.45)
Total	93.94 (11.31)	95.33 (9.91)	88.75 (14.05)

Results of the WHOQOL-OLD questionnaire. Values of the subgroups with lowest and highest amyloid load (Amyloid quartile 1 and 4) are displayed.

<https://doi.org/10.1371/journal.pone.0247225.t003>

To test for a potential influence of covariates (age, sex and education) a parametric univariate statistics (general linear model) was computed with Box-Cox transformed variables. The corrected model ($F_{(6,48)} = 2.43$, $p = 0.042$, partial eta squared = 0.257). The effects of the covariates were not significant (all $p > 0.05$ and partial eta squared < 0.09) but the effect of the fixed factor amyloid-load (amyloid quartiles) was significant ($F_{(3,48)} = 3.879$, $p = 0.016$, partial eta squared = 0.217) showing an effect on the dependent variable autonomy.


Association of amyloid with neuroticism and extraversion scores

The scores measured with the German version of the NeoFFI [87] were 15.3 (SD 6.6) for neuroticism, 25 (SD 5.9) for extraversion, 28 (SD 6.8) for openness for experience, 34.7 (SD 5.8) for agreeableness and 35.2 (SD 6) for conscientiousness.

Scores for neuroticism (Kruskal-Wallis 9.18, $p = 0.027$) and extraversion (Kruskal-Wallis 15.22, $p = 0.002$) were significantly different among the quartiles of amyloid-distribution. Visually the quartile with the highest amyloid-load showed reduced extraversion and increased neuroticism compared to Q1-3. Mann-Whitney U post hoc test between Q4 and Q1-3 showed for both significant results (neuroticism Mann-Whitney U = 319.5, $p = 0.023$; extraversion U = 106, $p = 0.007$).

To test for the influence of age, sex and education a multivariate analysis for repeated measures (NeoFFI as repeated measure with neuroticism and extraversion) with these covariates and factor amyloid load was performed with Box-Cox transformed variables. No significance for the repeated factor NeoFFI or the covariates ($p > 0.6$) except for factor amyloid quartiles ($F_{(3,42)} = 6.515$, $p = 0.001$, partial eta squared 0.318) (significance remained unaffected by a Greenhouse-Geisser correction as compared to the assumption of sphericity). Fig 2 depicts the marginal means of the two NeoFFI scores against SUVR Quartiles. The comparison between Q1-3 and Q4 amyloid load groups revealed similar results which only amyloid as significant effect with NEOFFI ($F_{(3,44)} = 10.33$, $p = 0.002$, partial eta squared 0.190).

Also for between-subjects effects for both personality traits univariate tested the factor amyloid quartiles was significant (neuroticism: $F_{(3,48)} = 3.498$, $p = 0.024$, partial eta squared = 0.200; extraversion: $F_{(3,48)} = 5.623$, $p = 0.002$, partial eta squared = 0.287). None of the covariates were significant. The corrected model showed a significant effect for extraversion ($F_{(6,48)}$)



Covariates appearing in the model are evaluated at the following values: age_boxcox = .0000, education in years_boxcox = .0000, sex = .31

Fig 2. Plot of estimated marginal means of extraversion and neuroticism score against amyloid load. Plot of the estimated marginal means of the two NeoFFI measures as estimated in the repeated measures model with the covariates age, sex and education. Neuroticism against amyloid quartiles is plotted in blue and extraversion in red. Variables were Box-Cox transformed.

<https://doi.org/10.1371/journal.pone.0247225.g002>

= 2.940, $p = 0.017$, partial eta squared 0.296) and showed no significance for neuroticism ($F(6,48) = 2.005$, $p = 0.086$, partial eta squared = 0.223).

Participants with lower amyloid-load (Q1-Q3 only) showed a visual but not significant trend of reduced neuroticism scores with higher amyloid-load ($\rho = -0.233$, $p = 0.164$) and a significant positive correlation with extraversion ($\rho = 0.402$, $p = 0.014$). SUVR values ranging from Q1-Q3 are normal distributed (Kolmogorov-Smirnov $Z = 0.082$, $p = 0.2$).

When performing a partial correlation with control variables age, sex and education and SUVR with all NEOFFI scores extraversion was significantly correlating with SUVR ($r = 0.39$, $p = 0.023$, $df = 32$) while neuroticism was not ($r = -0.236$, $p = 0.178$, $df = 32$). For this test, all variables were transformed within the reduced sample.

Total brain volume-corrected hippocampal volume showed a significant correlation with agreeableness ($\rho = -0.308$, $p = 0.031$) but none for the other traits. Five comparisons were made for each research question. Performing a partial correlation with age, sex and education as covariates no correlation was significant ($p > 0.080$, with Box-Cox transformed variables).

Potential protective factors—current physical and cognitive activities

The scores for cognitive activity were ranging from 5–37 and for physical score from 2–35. Values of the score also for subgroups for amyloid load, ApoE genotype and sex are listed in Table 4.

Physical but not cognitive activity over the last 12 months correlated negatively with cortical amyloid deposition ($\rho = -0.307$, $p = 0.032$) see also Fig 3. Neither score correlated with corrected hippocampal volume.

Performing a partial regression with age, sex and education as covariates the correlation did remain significant ($r = -0.303$, $p = 0.041$, $df = 44$, performed with transformed variables). Neither age, sex nor education did correlate with a Spearman's correlation with physical activity score ($p > 0.27$).

Table 4. Results of the cognitive and physical activity questionnaire.

		cognitive activities	physical activities
Amyloid Quartiles (N)			
1 (12)	Mean	20.6 (7.2)	11.9 (4.2)
2 (12)	Mean	20.5 (7.9)	10.5 (5.5)
3 (13)	Mean	20.7 (7.5)	10.5 (8.3)
4 (12)	Mean	21.3 (5.4)	9.3 (5.1)
ApoE Genotype (N)			
E2/E3 (9)	Mean	23.3 (6.5)	15.9 (8.5)
E2/E4 (3)	Mean	26.0 (5.5)	12.8 (4.3)
E3/E3 (34)	Mean	20.0 (6.9)	9.0 (4.7)
E3/E4 (3)	Mean	17.3 (6.8)	9.7 (1.3)
sex (N)			
female (15)	Mean	23.3 (8.0)	11.8 (8.2)
male (34)	Mean	19.7 (6.1)	10.0 (4.7)
Total (49)	Mean	20.8 (6.9)	10.6 (5.9)

Table 4: Results of the activity questionnaire with respect to Amyloid load, APOE or sex group. Mean values with standard deviation in parentheses are listed.

<https://doi.org/10.1371/journal.pone.0247225.t004>




Fig 3. Correlation physical activity score against amyloid SUVR. Scatter plot between physical activity score and amyloid SUVR. The correlation is significant ($\rho = -0.307$, $p = 0.032$) and indicates that participants with higher physical activity have lower amyloid SUVR.

<https://doi.org/10.1371/journal.pone.0247225.g003>

Effects of lifetime experiences

Educational, work-related and extracurricular activities measured with the lifetime experience questionnaire's (LEQ) [85] were neither associated with cortical amyloid-load nor with hippocampal volume. On average, our sample had a total LEQ of 89.12 (SD 13.1, range 60–120).

Importantly, total lifetime experience correlated with the executive function score ($p = 0.014$, $\rho = 0.367$) but not with the other assessed cognitive domains. Detailed analysis of the three executive-function subscores revealed that the error control score correlated most strongly with extracurricular and total lifetime experience in all three age stages. The strongest associations were observed for the non-specific subscores (extracurricular activities) but neither for work nor education-related experiences. The partial correlation with covariates age, sex and education showed similar results.

Fig 4 one correlation between midlife extracurricular experiences and executive cognitive function score is visualized. The correlation matrix between the LEQ items and the executive function scores is visualized in Fig 5 including indications of significance levels for Spearman's correlation and partial correlation with covariates.

Discussion

Our selected sample of participants has aged beyond the age of 85 without dementia and with preserved activities of daily living. We have seen that biological markers of Alzheimer's disease (amyloid and hippocampal volume) and cognitive performance were not related to each other in a way that would reflect the AD typical biomarker scheme where high amyloid and reduced hippocampal volume are related to lower cognitive performance [15, 90].

High amyloid load- may be associated with lower quality of life and a change in personality

Despite the absence of significant cognitive-amyloid or cognitive-hippocampal volume correlations, we found early signs of amyloid-related effects outside the cognitive domain. We showed the impact of high amyloid load on quality of life with respect to the experience of autonomy and on personality scores.




Fig 4. Correlation between midlife extracurricular experiences and executive cognitive functions. Significant correlation between executive function scores and midlife extracurricular experiences (measured with LEQ). Spearman's $\rho = 0.513$, $p < 0.001$ or Pearson's partial correlation (with covariates age, sex and education and Box-Cox corrected variables) $r = 0.499$, $p = 0.001$. Color indicates amyloid load quartiles (Quartile 1 lowest and Quartile 4 highest amyloid SUVR).

<https://doi.org/10.1371/journal.pone.0247225.g004>

With respect to a putative impact of personality, our findings indicate that personality traits like extraversion and neuroticism are related to amyloid-load. However, we are examining a sample with relatively low scores for neuroticism and a high quality of life. Our study population showed personality scores comparable to the general population [91], and a 65+ years population in Switzerland [92], with slightly lower neuroticism in our sample. Participants in the highest amyloid-load quartile displayed higher scores for neuroticism and lower scores for extraversion than the three lower amyloid quartiles. This effect was not monotonous along the entire range of amyloid-load.

Increased neuroticism seems to be a preceding signal for dementia [43, 93] as well as for mild cognitive impairment [94, 95]. A study with healthy volunteers (average age 81 years) showed a link between high neuroticism and beta-amyloid deposition in subjects with subjective cognitive complaints [96]. In our smaller and older sample, we did not see the same interaction but subjective memory complaints went with higher neuroticism scores. Various studies have shown changes in personality preceding dementia diagnosis [41, 42, 71, 97, 98]. We therefore suspect a subtle personality change in the high-amyloid subjects rather than a direct biological link as a mechanism to explain the relation.

In addition, we found that subjects with higher amyloid-load had a reduced autonomy score in the quality of life questionnaire. This is consistent with our findings on higher neuroticism and an additional indication that even in subjects with high cognitive reserve, amyloid pathology may become reflected in other, non-cognitive aspects.

The influence of physical and cognitive activities

We found an association of current physical activity with amyloid deposition, but neither with hippocampal volume nor cognitive measures, in our exceptional agers. The literature on a direct effect of physical activity on amyloid deposition in humans is less compelling than in animal models [99]. Nevertheless, several cross-sectional studies have already shown lower brain amyloidosis in participants with higher physical activity [45–47]. A recent longitudinal




Fig 5. Correlation matrix between lifetime-experiences and executive cognitive functions. Correlation matrix between executive functions scores and Lifetime experience questionnaire scores. Color and numbers indicate the Spearman's rho value. Color white indicates non-significance ($p > 0.05$). Stars indicating significance level in the Spearman's correlation and circles significance in the partial correlation with corrected variables (* or ° indicates significance on $p = 0.05$ level and ** or °° indicates significance on $p = 0.01$ level).

<https://doi.org/10.1371/journal.pone.0247225.g005>

study in healthy participants (average 73.4 years) found that more physical activity was associated to slower amyloid related cognitive decline and gray matter volume loss [100]. As we have no longitudinal data on physical activity, we cannot exclude that reduced physical activity could also be a consequence of increased amyloid-deposition that would be consistent with our findings on autonomy and personality.

Lifetime experience contributes to executive functioning

One of the most important protective factors for good cognitive functions at high age is cognitive reserve [30, 90, 101–103]. Our sample displayed a lower amount of cognitive complaints than others [104] which may reflect that our sample consisted of selected cognitively healthy individuals with a high cognitive reserve. Even in our sample, we found lifetime experience and especially extracurricular activities to go alongside with better executive functions in older age. Our results therefore underscore the direct relevance of lifetime experience for executive functioning. This effect did not seem to be mediated by pathology, as increased experience was not correlated with amyloid deposition or hippocampal volume.

In a younger cohort (66–88 years old) a similar relationship between lifestyle and cognition has been shown with a general measure of cognitive ability but without including information about AD biomarkers [50]. A recent study in 330 younger participants without dementia found no effect of midlife cognitive activities on late life amyloid accumulation (i.e., altering pathogenesis) but an effect on late life cognitive performance [105]. Concerning lifetime

experience and hippocampal volume a systematic meta-analysis identified an association [106] even though not all studies showed this relationship [32]. However, in a slightly younger population (average 80.8 years) of cognitively intact subjects, a positive correlation between lifetime experience and hippocampal volume was seen, especially with midlife experience score [39].

Especially participants with higher self-paced motivated extracurricular activities profit from better executive functions scores at later life [101, 102, 107–109]. Executive functioning is crucial for mastering everyday life: A recent study demonstrated in 452 MCI patients that executive function is crucial for progression of MCI to dementia [110]. Thus, strengthening lifetime experience and especially extracurricular activities may serve as a central strategy to prevent or increase time to conversion in dementia of all kind, irrespective of pathology.

Hippocampal volume shows no typical association with memory performance

The negative correlations between hippocampal volume and neuropsychological test performance in our sample were rather unexpected in older adult cohorts (though not unique, see [111]), but have been repeatedly described in younger subjects [112, 113]. In the current cross-sectional analysis, we cannot test if hippocampal atrophy is a risk for further cognitive decline. A recent longitudinal study where non-demented 82+ year old participants were followed up for 7–15 years showed a significant association with memory decline and isolated hippocampal atrophy (in absence of amyloid positive deposition) [114]. In the same study, isolated amyloid positivity (preserved hippocampal volume) was associated with memory and executive decline, while at baseline the effect of amyloid deposition was not significant.

Methodological considerations

Our sample included only 30.6% women. This is less than in other cohorts and does not reflect the sex proportion in this age group in the general population [115, 116]. Distribution of ApoE genotypes in our sample was similar to other studies in exceptional aging showing low frequencies of the epsilon 4 allele and high frequencies of the epsilon 2 allele. [115–117].

With our sample size and statistical methods, we were only able to detect moderate to strong associations so we cannot rule out subtler effects on AD-biomarkers that would have been uncovered with larger sample sizes, but could still play an important role on an epidemiological level.

We had a power of 83% to detect correlations with effect size of $\rho = 0.4$. For weaker correlations (i.e., $\rho = 0.3$) we only had a power of 56% in our sample.

As this is an exploratory study we chose not to correct our p-values for multiple testing as discussed in detail by others [118]. For all studied comparisons and associations, a scientific rationale existed a priori. In order to capture the specifics of this sample under study we present the different aspects of the study within one publication. We believe that this provides the reader with a more comprehensive picture of the data even if this leads to more comparisons within one publication.

We used state of the art and highly standardized imaging as well as clinical assessment methods to characterize biomarkers, health status and lifestyle factors in this sample. We carefully executed dedicated imaging analysis, taking care of the advanced age of this group and ensuring reliable values.

Conclusion

We have seen that features of Alzheimer's pathology occur frequently at higher age in healthy subjects in the absence of dementia. However, the typical association of amyloid with

hippocampal volume loss and impaired memory function, which characterizes the pathway to Alzheimer's disease, is not present in these exceptional agers.

Importantly, our results indicate that even in exceptional aging, high amyloid load may have already subtle effects on personality and quality of life irrespective of effects on cognition. We support the notion of a protective effect of physical activity on amyloid-deposition. In addition, extracurricular lifetime experience plays an important role for later executive cognitive functions irrespective of Alzheimer's pathology and thus enhancing such experience may serve as a general protective strategy for dementia.

Supporting information

S1 Table. Test for normal distribution with continuous variables of interest.

(DOCX)

S2 Table. Key parameters grouped in accordance with ApoE genotype.

(DOCX)

Acknowledgments

The technologists of the PET/CT/MR Center at the Department of Nuclear Medicine University Hospital Zurich and especially Marlena Hofbauer and Sabrina Epp. The whole study team and database team of the Institute of Regenerative Medicine of the University of Zurich.

Author Contributions

Conceptualization: Valerie Treyer, Roger M. Nitsch, Christoph Hock, Anton F. Gietl.

Data curation: Valerie Treyer, Rafael S. Meyer, Andreas Buchmann, Sandro Studer, Antje Saake, Esmeralda Gruber, Anton F. Gietl.

Formal analysis: Valerie Treyer, Andreas Buchmann, Giovanni A. G. Cramer.

Funding acquisition: Valerie Treyer, Roger M. Nitsch, Christoph Hock, Anton F. Gietl.

Investigation: Valerie Treyer, Rafael S. Meyer, Andreas Buchmann, Sandro Studer, Antje Saake, Esmeralda Gruber, Anton F. Gietl.

Methodology: Valerie Treyer, Andreas Buchmann, Paul G. Unschuld, Christoph Hock, Anton F. Gietl.

Project administration: Valerie Treyer, Rafael S. Meyer, Andreas Buchmann, Sandro Studer, Antje Saake, Esmeralda Gruber, Anton F. Gietl.

Resources: Roger M. Nitsch, Christoph Hock.

Supervision: Valerie Treyer, Anton F. Gietl.

Visualization: Valerie Treyer, Andreas Buchmann, Anton F. Gietl.

Writing – original draft: Valerie Treyer, Andreas Buchmann, Giovanni A. G. Cramer, Anton F. Gietl.

Writing – review & editing: Valerie Treyer, Rafael S. Meyer, Andreas Buchmann, Giovanni A. G. Cramer, Sandro Studer, Antje Saake, Esmeralda Gruber, Paul G. Unschuld, Roger M. Nitsch, Christoph Hock, Anton F. Gietl.

References

1. International AsD. World Alzheimer Report 2019: Attitudes to dementia. London: Alzheimer's Disease International, 2019.
2. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. *Neurology*. 2012; 78(19):1456–63. <https://doi.org/10.1212/WNL.0b013e3182553be6> PMID: 22551732.
3. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. *N Engl J Med*. 2013; 369(24):2275–7. <https://doi.org/10.1056/NEJMp1311405> PMID: 24283198; PubMed Central PMCID: PMC4130738.
4. Brenowitz WD, Monsell SE, Schmitt FA, Kukull WA, Nelson PT. Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical-pathologic correlations and comparisons with both Alzheimer's disease and non-tauopathic frontotemporal lobar degeneration. *J Alzheimers Dis*. 2014; 39(3):691–702. <https://doi.org/10.3233/JAD-131880> PMID: 24270205; PubMed Central PMCID: PMC3946156.
5. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). *J Neuropathol Exp Neurol*. 2005; 64(2):156–62. Epub 2005/03/09. <https://doi.org/10.1093/jnen/64.2.156> PMID: 15751230.
6. Jellinger KA, Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. *Journal of the neurological sciences*. 2005; 229–230:37–41. Epub 2005/03/12. <https://doi.org/10.1016/j.jns.2004.11.018> PMID: 15760617.
7. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain*. 2019; 142(6):1503–27. Epub 2019/05/01. <https://doi.org/10.1093/brain/awz099> PMID: 31039256; PubMed Central PMCID: PMC6536849.
8. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. *Ann Neurol*. 2011; 70(5):857–61. <https://doi.org/10.1002/ana.22608> PMID: 22162065; PubMed Central PMCID: PMC3243969.
9. Roberts RO, Aakre JA, Kremers WK, Vassilaki M, Knopman DS, Mielke MM, et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. *JAMA Neurol*. 2018; 75(8):970–9. <https://doi.org/10.1001/jamaneurol.2018.0629> PMID: 29710225; PubMed Central PMCID: PMC6142936.
10. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann Neurol*. 2011; 69(1):181–92. <https://doi.org/10.1002/ana.22248> PMID: 21280088; PubMed Central PMCID: PMC3045039.
11. Ossenkoppelle R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. *Jama*. 2018; 320(11):1151–62. Epub 2018/10/17. <https://doi.org/10.1001/jama.2018.12917> PMID: 30326496; PubMed Central PMCID: PMC6233630.
12. Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. *Brain*. 2019; 142(6):1723–35. Epub 2019/04/23. <https://doi.org/10.1093/brain/awz090> PMID: 31009046; PubMed Central PMCID: PMC6536847.
13. Sullivan KJ, Liu A, Chang CH, Cohen AD, Lopresti BJ, Minhas DS, et al. Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. *Brain imaging and behavior*. 2020. Epub 2020/08/05. <https://doi.org/10.1007/s11682-020-00334-2> PMID: 32748322.
14. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers & Dementia*. 2011; 7(3):280–92. WOS:000291239600005. <https://doi.org/10.1016/j.jalz.2011.03.003> PMID: 21514248
15. Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology*. 2016; 87(5):539–47. <https://doi.org/10.1212/WNL.0000000000002923> PMID: 27371494; PubMed Central PMCID: PMC4970664.
16. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement*. 2016; 12(3):292–323. Epub 2016/03/26. <https://doi.org/10.1016/j.jalz.2016.02.002> PMID: 27012484; PubMed Central PMCID: PMC6417794.

17. Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr., Lovblad KO, et al. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. *Neurobiol Aging*. 2017; 52:167–82.e1. Epub 2017/03/21. <https://doi.org/10.1016/j.neurobiolaging.2016.05.024> PMID: 28317647.
18. Martin SB, Smith CD, Collins HR, Schmitt FA, Gold BT. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. *Neurobiology of Aging*. 2010; 31(7):1099–106. <https://doi.org/10.1016/j.neurobiolaging.2008.08.010> PMID: 18809227
19. Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. *Neurobiology of Aging*. 2010; 31(7):1077–88. <https://doi.org/10.1016/j.neurobiolaging.2008.08.008> PMID: 18814937
20. Valenzuela MJ, Sachdev P, Wen W, Chen X, Brodaty H. Lifespan mental activity predicts diminished rate of hippocampal atrophy. *PLoS One*. 2008; 3(7):e2598. Epub 2008/07/10. <https://doi.org/10.1371/journal.pone.0002598> PMID: 18612379; PubMed Central PMCID: PMC2440814.
21. Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. *Nat Rev Neurol*. 2012; 8(4):189–202. Epub 2012/03/14. <https://doi.org/10.1038/nrneurol.2012.27> PMID: 22410582.
22. Tabatabaei-Jafari H, Shaw ME, Cherbuin N. Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysis. *Alzheimers Dement (Amst)*. 2015; 1(4):487–504. Epub 2016/05/31. <https://doi.org/10.1016/j.dadm.2015.11.002> PMID: 27239527; PubMed Central PMCID: PMC4879488.
23. Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff-Radford J, et al. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. *JAMA Neurol*. 2017; 74(6):718–26. Epub 2017/04/19. <https://doi.org/10.1001/jamaneurol.2017.0244> PMID: 28418521; PubMed Central PMCID: PMC5649401.
24. Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, et al. Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. *Alzheimers Dement*. 2013; 9(2):199–203. <https://doi.org/10.1016/j.jalz.2012.06.005> PMID: 23164550; PubMed Central PMCID: PMC3604036.
25. Lucca U, Garri M, Recchia A, Logroscino G, Tiraboschi P, Franceschi M, et al. A Population-based study of dementia in the oldest old: the Monzino 80-plus study. *BMC Neurol*. 2011; 11:54. <https://doi.org/10.1186/1471-2377-11-54> PMID: 21612585; PubMed Central PMCID: PMC3120664.
26. Imhof A, Kovari E, von Gunten A, Gold G, Rivara CB, Herrmann FR, et al. Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? *Journal of the neurological sciences*. 2007; 257(1–2):72–9. Epub 2007/02/17. <https://doi.org/10.1016/j.jns.2007.01.025> PMID: 17303173.
27. Gallagher M, Okonkwo OC, Resnick SM, Jagust WJ, Benzinger TLS, Rapp PR. What are the threats to successful brain and cognitive aging? *Neurobiol Aging*. 2019; 83:130–4. Epub 2019/11/17. <https://doi.org/10.1016/j.neurobiolaging.2019.04.016> PMID: 31732016; PubMed Central PMCID: PMC6859944.
28. Carapelle E, Serra L, Modoni S, Falcone M, Caltagirone C, Bozzali M, et al. How the cognitive reserve interacts with beta-amyloid deposition in mitigating FDG metabolism: An observational study. *Medicine (Baltimore)*. 2017; 96(16):e5876. <https://doi.org/10.1097/MD.0000000000005876> PMID: 28422821; PubMed Central PMCID: PMC5406037.
29. Bauckneht M, Picco A, Nobili F, Morbelli S. Amyloid positron emission tomography and cognitive reserve. *World J Radiol*. 2015; 7(12):475–83. <https://doi.org/10.4329/wjr.v7.i12.475> PMID: 26753062; PubMed Central PMCID: PMC4697121.
30. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. *Lancet Neurol*. 2012; 11(11):1006–12. [https://doi.org/10.1016/S1474-4422\(12\)70191-6](https://doi.org/10.1016/S1474-4422(12)70191-6) PMID: 23079557; PubMed Central PMCID: PMC3507991.
31. Nyberg L, Lovden M, Riklund K, Lindenberger U, Backman L. Memory aging and brain maintenance. *Trends Cogn Sci*. 2012; 16(5):292–305. Epub 2012/05/01. <https://doi.org/10.1016/j.tics.2012.04.005> PMID: 22542563.
32. Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Roberts RO, Lowe VJ, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. *Ann Neurol*. 2012; 72(5):730–8. Epub 2013/01/03. <https://doi.org/10.1002/ana.23665> PMID: 23280791; PubMed Central PMCID: PMC3539211.
33. Frederiksen KS, Gjerum L, Waldemar G, Hasselbalch SG. Effects of Physical Exercise on Alzheimer's Disease Biomarkers: A Systematic Review of Intervention Studies. *J Alzheimers Dis*. 2018; 61(1):359–72. <https://doi.org/10.3233/JAD-170567> PMID: 29154278.
34. Lautenschlager NT, Cox KL, Ellis KA. Physical activity for cognitive health: what advice can we give to older adults with subjective cognitive decline and mild cognitive impairment? *Dialogues in clinical*

- neuroscience. 2019; 21(1):61–8. Epub 2019/10/15. <https://doi.org/10.31887/DCNS.2019.21.1/nlautenschlager> PMID: 31607781; PubMed Central PMCID: PMC6780362.
35. De la Rosa A, Olaso-Gonzalez G, Arc-Chagnaud C, Millan F, Salvador-Pascual A, García-Lucerga C, et al. Physical exercise in the prevention and treatment of Alzheimer's disease. *Journal of sport and health science*. 2020; 9(5):394–404. Epub 2020/08/12. <https://doi.org/10.1016/j.jshs.2020.01.004> PMID: 32780691; PubMed Central PMCID: PMC7498620.
 36. Gow AJ, Pattie A, Deary IJ. Lifecourse Activity Participation From Early, Mid, and Later Adulthood as Determinants of Cognitive Aging: The Lothian Birth Cohort 1921. *J Gerontol B Psychol Sci Soc Sci*. 2017; 72(1):25–37. Epub 2016/12/16. <https://doi.org/10.1093/geronb/gbw124> PMID: 27974473; PubMed Central PMCID: PMC5156497.
 37. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. *Jama*. 1994; 271(13):1004–10. Epub 1994/04/06. PMID: 8139057.
 38. Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence of Alzheimer's disease. *Neurology*. 2001; 57(12):2236–42. Epub 2002/01/05. <https://doi.org/10.1212/wnl.57.12.2236> PMID: 11756603; PubMed Central PMCID: PMC3025284.
 39. Suo C, Leon I, Brodaty H, Trollor J, Wen W, Sachdev P, et al. Supervisory experience at work is linked to low rate of hippocampal atrophy in late life. *Neuroimage*. 2012; 63(3):1542–51. Epub 2012/08/21. <https://doi.org/10.1016/j.neuroimage.2012.08.015> PMID: 22902920.
 40. Rodriguez FS, Roehr S, Pabst A, Kleineidam L, Fuchs A, Wiese B, et al. Effects of APOE e4-allele and mental work demands on cognitive decline in old age: Results from the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe). *Int J Geriatr Psychiatry*. 2020. Epub 2020/08/21. <https://doi.org/10.1002/gps.5409> PMID: 32819031.
 41. Balsis S, Carpenter BD, Storandt M. Personality change precedes clinical diagnosis of dementia of the Alzheimer type. *J Gerontol B Psychol Sci Soc Sci*. 2005; 60(2):P98–P101. Epub 2005/03/05. <https://doi.org/10.1093/geronb/60.2.p98> PMID: 15746024.
 42. Low LF, Harrison F, Lackersteen SM. Does personality affect risk for dementia? A systematic review and meta-analysis. *Am J Geriatr Psychiatry*. 2013; 21(8):713–28. <https://doi.org/10.1016/j.jagp.2012.08.004> PMID: 23567438.
 43. Yoneda T, Rush J, Berg AI, Johansson B, Piccinin AM. Trajectories of Personality Traits Preceding Dementia Diagnosis. *J Gerontol B Psychol Sci Soc Sci*. 2017; 72(6):922–31. Epub 2016/03/06. <https://doi.org/10.1093/geronb/gbw006> PMID: 26945005; PubMed Central PMCID: PMC5927080.
 44. Wilson RS, Begeny CT, Boyle PA, Schneider JA, Bennett DA. Vulnerability to stress, anxiety, and development of dementia in old age. *Am J Geriatr Psychiatry*. 2011; 19(4):327–34. Epub 2011/03/24. <https://doi.org/10.1097/JGP.0b013e31820119da> PMID: 21427641; PubMed Central PMCID: PMC3078621.
 45. Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, et al. Physical activity and amyloid-beta plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. *Mol Psychiatry*. 2013; 18(8):875–81. Epub 2012/08/15. <https://doi.org/10.1038/mp.2012.107> PMID: 22889922.
 46. Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, et al. Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. *Arch Neurol*. 2012; 69(5):636–43. Epub 2012/01/11. <https://doi.org/10.1001/archneurol.2011.845> PMID: 22232206; PubMed Central PMCID: PMC3583203.
 47. Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. *Ann Neurol*. 2010; 68(3):311–8. Epub 2010/09/08. <https://doi.org/10.1002/ana.22096> PMID: 20818789; PubMed Central PMCID: PMC2936720.
 48. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al. Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. *Jama*. 2015; 314(8):781–90. Epub 2015/08/26. <https://doi.org/10.1001/jama.2015.9617> PMID: 26305648; PubMed Central PMCID: PMC4698980.
 49. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise training increases size of hippocampus and improves memory. *Proc Natl Acad Sci U S A*. 2011; 108(7):3017–22. Epub 2011/02/02. <https://doi.org/10.1073/pnas.1015950108> PMID: 21282661; PubMed Central PMCID: PMC3041121.
 50. Chan D, Shafto M, Kievit R, Matthews F, Spink M, Valenzuela M, et al. Lifestyle activities in mid-life contribute to cognitive reserve in late-life, independent of education, occupation, and late-life activities. *Neurobiol Aging*. 2018; 70:180–3. Epub 2018/07/20. <https://doi.org/10.1016/j.neurobiolaging.2018.06.012> PMID: 30025291; PubMed Central PMCID: PMC6805221.

51. Wirth M, Haase CM, Villeneuve S, Vogel J, Jagust WJ. Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. *Neurobiol Aging*. 2014; 35(8):1873–82. Epub 2014/03/25. <https://doi.org/10.1016/j.neurobiolaging.2014.02.015> PMID: 24656834; PubMed Central PMCID: PMC4019766.
52. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Education modifies the association of amyloid but not tangles with cognitive function. *Neurology*. 2005; 65(6):953–5. Epub 2005/09/28. <https://doi.org/10.1212/01.wnl.0000176286.17192.69> PMID: 16186546.
53. Wilson RS, Yu L, Lamar M, Schneider JA, Boyle PA, Bennett DA. Education and cognitive reserve in old age. *Neurology*. 2019; 92(10):e1041–e50. Epub 2019/02/08. <https://doi.org/10.1212/WNL.0000000000007036> PMID: 30728309; PubMed Central PMCID: PMC6442015.
54. Lamar M, Boots EA, Arfanakis K, Barnes LL, Schneider JA. Common Brain Structural Alterations Associated with Cardiovascular Disease Risk Factors and Alzheimer's Dementia: Future Directions and Implications. *Neuropsychology review*. 2020. Epub 2020/10/05. <https://doi.org/10.1007/s11065-020-09460-6> PMID: 33011894.
55. Olaya B, Moneta MV, Bobak M, Haro JM, Demakakos P. Cardiovascular risk factors and memory decline in middle-aged and older adults: the English Longitudinal Study of Ageing. *BMC geriatrics*. 2019; 19(1):337. Epub 2019/12/04. <https://doi.org/10.1186/s12877-019-1350-5> PMID: 31791248; PubMed Central PMCID: PMC6889660.
56. Solomon A, Kivipelto M, Soininen H. Prevention of Alzheimer's disease: moving backward through the lifespan. *J Alzheimers Dis*. 2013; 33 Suppl 1:S465–9. Epub 2012/07/04. <https://doi.org/10.3233/JAD-2012-129021> PMID: 22751171.
57. Juul Rasmussen I, Rasmussen KL, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-Schmidt R. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. *Eur Heart J*. 2020. Epub 2020/10/07. <https://doi.org/10.1093/eurheartj/ehaa695> PMID: 33022702.
58. Pugazhenth S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. *Biochimica et biophysica acta Molecular basis of disease*. 2017; 1863(5):1037–45. Epub 2016/05/10. <https://doi.org/10.1016/j.bbadis.2016.04.017> PMID: 27156888; PubMed Central PMCID: PMC5344771.
59. Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Machulda M, Lowe VJ, et al. Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. *Neurology*. 2016; 86(12):1128–35. Epub 2016/02/26. <https://doi.org/10.1212/WNL.0000000000002490> PMID: 26911640; PubMed Central PMCID: PMC4820132.
60. Fratiglioni L, Marseglia A, Dekhtyar S. Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference? *Lancet Neurol*. 2020; 19(6):533–43. Epub 2020/05/30. [https://doi.org/10.1016/S1474-4422\(20\)30039-9](https://doi.org/10.1016/S1474-4422(20)30039-9) PMID: 32470425.
61. McMaster M, Kim S, Clare L, Torres SJ, Cherbuin N, D'Este C, et al. Lifestyle Risk Factors and Cognitive Outcomes from the Multidomain Dementia Risk Reduction Randomized Controlled Trial, Body Brain Life for Cognitive Decline (BBL-CD). *J Am Geriatr Soc*. 2020. Epub 2020/09/11. <https://doi.org/10.1111/jgs.16762> PMID: 32909259.
62. Bott NT, Hall A, Madero EN, Glenn JM, Fuseya N, Gills JL, et al. Face-to-Face and Digital Multidomain Lifestyle Interventions to Enhance Cognitive Reserve and Reduce Risk of Alzheimer's Disease and Related Dementias: A Review of Completed and Prospective Studies. *Nutrients*. 2019; 11(9). Epub 2019/09/25. <https://doi.org/10.3390/nu11092258> PMID: 31546966; PubMed Central PMCID: PMC6770494.
63. Lista S, Dubois B, Hampel H. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. *J Nutr Health Aging*. 2015; 19(2):154–63. <https://doi.org/10.1007/s12603-014-0515-3> PMID: 25651440.
64. Rogalski E, Gefen T, Mao Q, Connelly M, Weintraub S, Geula C, et al. Cognitive trajectories and spectrum of neuropathology in SuperAgers: The first 10 cases. *Hippocampus*. 2019; 29(5):458–67. Epub 2018/01/18. <https://doi.org/10.1002/hipo.22828> PMID: 29341318; PubMed Central PMCID: PMC6050141.
65. Vemuri P. "Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game. *Alzheimers Res Ther*. 2018; 10(1):53. Epub 2018/06/03. <https://doi.org/10.1186/s13195-018-0373-z> PMID: 29859131; PubMed Central PMCID: PMC5984828.
66. Burke SN, Mormino EC, Rogalski EJ, Kawas CH, Willis RJ, Park DC. What are the later life contributions to reserve, resilience, and compensation? *Neurobiol Aging*. 2019; 83:140–4. Epub 2019/11/17. <https://doi.org/10.1016/j.neurobiolaging.2019.03.023> PMID: 31732017; PubMed Central PMCID: PMC6989050.

67. Kim MJ, Seo SW, Kim GH, Kim ST, Lee JM, Qiu A, et al. Less depressive symptoms are associated with smaller hippocampus in subjective memory impairment. *Arch Gerontol Geriatr*. 2013; 57(1):110–5. Epub 2013/03/07. <https://doi.org/10.1016/j.archger.2013.01.005> PMID: 23462582.
68. Norton DJ, Amariglio R, Protas H, Chen K, Aguirre-Acevedo DC, Pulsifer B, et al. Subjective memory complaints in preclinical autosomal dominant Alzheimer disease. *Neurology*. 2017; 89(14):1464–70. Epub 2017/09/08. <https://doi.org/10.1212/WNL.0000000000004533> PMID: 28878053; PubMed Central PMCID: PMC5631170.
69. Sutin AR, Stephan Y, Terracciano A. Psychological well-being and risk of dementia. *Int J Geriatr Psychiatry*. 2018; 33(5):743–7. Epub 2018/01/10. <https://doi.org/10.1002/gps.4849> PMID: 29314273; PubMed Central PMCID: PMC5882524.
70. Schmand B, Jonker C, Hooijer C, Lindeboom J. Subjective memory complaints may announce dementia. *Neurology*. 1996; 46(1):121–5. Epub 1996/01/01. <https://doi.org/10.1212/wnl.46.1.121> PMID: 8559359.
71. Terracciano A, Sutin AR, An Y, O'Brien RJ, Ferrucci L, Zonderman AB, et al. Personality and risk of Alzheimer's disease: new data and meta-analysis. *Alzheimers Dement*. 2014; 10(2):179–86. <https://doi.org/10.1016/j.jalz.2013.03.002> PMID: 23706517; PubMed Central PMCID: PMC3783589.
72. van Bergen JMG, Li X, Quevenco FC, Gietl AF, Treyer V, Leh SE, et al. Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. *Neurobiol Aging*. 2018; 64:68–75. <https://doi.org/10.1016/j.neurobiolaging.2017.12.014> PMID: 29351872; PubMed Central PMCID: PMC5820223.
73. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975; 12(3):189–98. Epub 1975/11/01. [https://doi.org/10.1016/0022-3956\(75\)90026-6](https://doi.org/10.1016/0022-3956(75)90026-6) PMID: 1202204.
74. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *The Gerontologist*. 1969; 9(3):179–86. Epub 1969/01/01. PMID: 5349366.
75. Hamilton M. A rating scale for depression. *Journal of neurology, neurosurgery, and psychiatry*. 1960; 23:56–62. <https://doi.org/10.1136/jnnp.23.1.56> PMID: 14399272; PubMed Central PMCID: PMC495331.
76. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013; 310(20):2191–4. Epub 2013/10/22. <https://doi.org/10.1001/jama.2013.281053> PMID: 24141714.
77. Thalman B, Monsch A.U., Bernasconi F., Berres M., Schneitter M., Ermini-Fuenfschilling D., editor. CERAD-Consortium to Establish a Registry for Alzheimer's Disease Assessment Battery-deutsche Fassung. Basel: Geriatriische Universitaetsklinik; 1997.
78. Delis D, Kaplan E., editor. Delis-Kaplan Executive Function Battery. San Antonio TX: Psychological Corporation; 2001.
79. Helmstaedter C, Lendt, M., Lux, S. Verbaler Lern- und Merkfähigkeitstest. In: GmbH BT, editor. Beltz Test. Göttingen2001.
80. Osterrieth P. Le test de copie d'une figure complexe. *Archives de Psychologie*. 1944; 30:206–356.
81. Taylor LB. Localization of cerebral lesions by psychological testing. *Clinical Neurosurgery*. 1969; 16:269–87. https://doi.org/10.1093/neurosurgery/16.cn_suppl_1.269 PMID: 5811709
82. Haerting C, Markowitsch H.J., Neufeld H., Calabrese P., Diesinger K., Kessler J., editor. Wechsler Gedächtnis Test- Revidierte Fassung (WMS-R). Bern: Hans Huber; 2000.
83. Regard M, Strauss E., Knapp P. Children's production on verbal and nonverbal fluency tasks. *Perceptual and Motor Skills*. 1982; 55(3 Pt 1):839–44.
84. Shallice T. Specific impairments of planning. *Philos Trans R Soc Lond B Biol Sci*. 1982; 298 (1089):199–209. Epub 1982/06/25. <https://doi.org/10.1098/rstb.1982.0082> PMID: 6125971.
85. Valenzuela MJ, Sachdev P. Assessment of complex mental activity across the lifespan: development of the Lifetime of Experiences Questionnaire (LEQ). *Psychol Med*. 2007; 37(7):1015–25. Epub 2006/11/23. <https://doi.org/10.1017/S003329170600938X> PMID: 17112402.
86. Winkler I, Matschinger H, Angermeyer MC. [The WHOQOL-OLD]. *Psychotherapie, Psychosomatik, medizinische Psychologie*. 2006; 56(2):63–9. Epub 2006/02/03. <https://doi.org/10.1055/s-2005-915334> PMID: 16453244.
87. Gerhard U, Borkenau P. & Ostendorf F. (1993). NEO-Fünf-Faktoren Inventar (NEO-FFI) nach Costa und McCrae. Göttingen: Hogrefe. Preis DM 84. 1999; 28(2):145–6. <https://doi.org/10.1026/0084-5345.28.2.145>
88. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr., Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015; 11(1):1–

- 15 e1–4. <https://doi.org/10.1016/j.jalz.2014.07.003> PMID: 25443857; PubMed Central PMCID: PMC4300247.
89. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. *Behavior research methods*. 2009; 41(4):1149–60. Epub 2009/11/10. <https://doi.org/10.3758/BRM.41.4.1149> PMID: 19897823.
 90. Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. *Radiology*. 2012; 263(2):344–61. <https://doi.org/10.1148/radiol.12110433> PMID: 22517954; PubMed Central PMCID: PMC3329271.
 91. Körner A, Drapeau M, Albani C, Geyer M, Schmutzer G, Brähler E. Deutsche Normierung des NEO-Fünf-Faktoren-Inventars (NEO-FFI). [German norms for the NEO-Five Factor Inventory.]. *Zeitschrift für Medizinische Psychologie*. 2008; 17(2–3):133–44.
 92. Ouanes S, Castela E, von Gunten A, Vidal PM, Preisig M, Popp J. Personality, Cortisol, and Cognition in Non-demented Elderly Subjects: Results from a Population-Based Study. *Front Aging Neurosci*. 2017; 9:63. Epub 2017/03/30. <https://doi.org/10.3389/fnagi.2017.00063> PMID: 28352228; PubMed Central PMCID: PMC5348534.
 93. Johansson L, Guo X, Duberstein PR, Hallstrom T, Waern M, Ostling S, et al. Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up. *Neurology*. 2014; 83(17):1538–44. <https://doi.org/10.1212/WNL.0000000000000907> PMID: 25274849.
 94. Caselli RJ, Langlais BT, Dueck AC, Henslin BR, Johnson TA, Woodruff BK, et al. Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment. *J Am Geriatr Soc*. 2018; 66(4):671–8. Epub 2018/01/18. <https://doi.org/10.1111/jgs.15182> PMID: 29341070; PubMed Central PMCID: PMC5906173.
 95. Mendez Rubio M, Antonietti JP, Donati A, Rossier J, von Gunten A. Personality traits and behavioural and psychological symptoms in patients with mild cognitive impairment. *Dementia and geriatric cognitive disorders*. 2013; 35(1–2):87–97. Epub 2013/02/01. <https://doi.org/10.1159/000346129> PMID: 23364170.
 96. Snitz BE, Weissfeld LA, Cohen AD, Lopez OL, Nebes RD, Aizenstein HJ, et al. Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. *Am J Geriatr Psychiatry*. 2015; 23(9):985–93. Epub 2015/03/10. <https://doi.org/10.1016/j.jagp.2015.01.008> PMID: 25746485; PubMed Central PMCID: PMC4532656.
 97. Smith-Gamble V, Baiyewu O, Perkins AJ, Gureje O, Hall KS, Ogunniyi A, et al. Informant reports of changes in personality predict dementia in a population-based study of elderly african americans and yoruba. *Am J Geriatr Psychiatry*. 2002; 10(6):724–32. Epub 2002/11/13. PMID: 12427581.
 98. Dawson DV, Welsh-Bohmer KA, Siegler IC. Premorbid personality predicts level of rated personality change in patients with Alzheimer disease. *Alzheimer Dis Assoc Disord*. 2000; 14(1):11–9. Epub 2000/03/16. <https://doi.org/10.1097/00002093-200001000-00002> PMID: 10718200.
 99. Brown BM, Peiffer J, Rainey-Smith SR. Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. *Ageing Res Rev*. 2019; 50:9–18. Epub 2019/01/08. <https://doi.org/10.1016/j.arr.2019.01.003> PMID: 30615936.
 100. Rabin JS, Klein H, Kim DR, Schultz AP, Yang HS, Hampton O, et al. Associations of Physical Activity and beta-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. *JAMA Neurol*. 2019. Epub 2019/07/18. <https://doi.org/10.1001/jamaneurol.2019.1879> PMID: 31312836; PubMed Central PMCID: PMC6635892.
 101. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. *Arch Neurol*. 2008; 65(11):1467–71. Epub 2008/11/13. <https://doi.org/10.1001/archneur.65.11.1467> PMID: 19001165; PubMed Central PMCID: PMC2752218.
 102. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. *Neurology*. 2018; 90(15):695–703. Epub 2018/03/30. <https://doi.org/10.1212/WNL.0000000000005303> PMID: 29592885; PubMed Central PMCID: PMC5894932.
 103. Soldan A, Pettigrew C, Albert M. Evaluating Cognitive Reserve Through the Prism of Preclinical Alzheimer Disease. *The Psychiatric clinics of North America*. 2018; 41(1):65–77. Epub 2018/02/08. <https://doi.org/10.1016/j.psc.2017.10.006> PMID: 29412849; PubMed Central PMCID: PMC5806143.
 104. Pires C, Silva D, Maroco J, Gino S, Mendes T, Schmand BA, et al. Memory complaints associated with seeking clinical care. *Int J Alzheimers Dis*. 2012; 2012:725329. Epub 2012/04/27. <https://doi.org/10.1155/2012/725329> PMID: 22536537; PubMed Central PMCID: PMC3320051.
 105. Rawlings AM, Sharrett AR, Mosley TH, Wong DF, Knopman DS, Gottesman RF. Cognitive Reserve in Midlife is not Associated with Amyloid-beta Deposition in Late-Life. *J Alzheimers Dis*. 2019; 68(2):517–21. Epub 2019/02/19. <https://doi.org/10.3233/JAD-180785> PMID: 30775981; PubMed Central PMCID: PMC6443418.

106. Anaturk M, Demnitz N, Ebmeier KP, Sexton CE. A systematic review and meta-analysis of structural magnetic resonance imaging studies investigating cognitive and social activity levels in older adults. *Neuroscience and biobehavioral reviews*. 2018; 93:71–84. Epub 2018/06/26. <https://doi.org/10.1016/j.neubiorev.2018.06.012> PMID: 29940239; PubMed Central PMCID: PMC6562200.
107. Forstmeier S, Maercker A. Motivational processes in mild cognitive impairment and Alzheimer's disease: results from the Motivational Reserve in Alzheimer's (MoReA) study. *BMC psychiatry*. 2015; 15:293. Epub 2015/11/19. <https://doi.org/10.1186/s12888-015-0666-8> PMID: 26578083; PubMed Central PMCID: PMC4650956.
108. Forstmeier S, Maercker A, Maier W, van den Bussche H, Riedel-Heller S, Kaduszkiewicz H, et al. Motivational reserve: motivation-related occupational abilities and risk of mild cognitive impairment and Alzheimer disease. *Psychology and aging*. 2012; 27(2):353–63. Epub 2011/08/31. <https://doi.org/10.1037/a0025117> PMID: 21875213.
109. Thoma MV, Forstmeier S, Schmid R, Kellner O, Xepapadacos F, Gasser US, et al. Preliminary evidence for an increased likelihood of a stable trajectory in mild cognitive impairment in individuals with higher motivational abilities. *BMC geriatrics*. 2018; 18(1):181. Epub 2018/08/15. <https://doi.org/10.1186/s12877-018-0865-5> PMID: 30103681; PubMed Central PMCID: PMC6090725.
110. Jung YH, Park S, Jang H, Cho SH, Kim SJ, Kim JP, et al. Frontal-executive dysfunction affects dementia conversion in patients with amnesic mild cognitive impairment. *Sci Rep*. 2020; 10(1):772. Epub 2020/01/23. <https://doi.org/10.1038/s41598-020-57525-6> PMID: 31964931; PubMed Central PMCID: PMC6972894.
111. Kohler S, Black SE, Sinden M, Szekely C, Kidron D, Parker JL, et al. Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer's disease. *Neuropsychologia*. 1998; 36(9):901–14. Epub 1998/09/18. [https://doi.org/10.1016/s0028-3932\(98\)00017-7](https://doi.org/10.1016/s0028-3932(98)00017-7) PMID: 9740363.
112. Chantome M, Perruchet P., Hasboun D., Dormont D., Sahel M., Sourour N., et al. Is there a negative correlation between explicit memory and hippocampal volume? *Neuroimage*. 1999; 10(10):589–95.
113. Foster JK, Meikler A., Goodson G., Mayes A.R., Howard M., Sunram S.I., et al. The hippocampus and delayed recall: Bigger is not necessarily better? *Memory*. 1999; 7(5–6):715–33. <https://doi.org/10.1080/096582199387823> PMID: 10659094
114. Zhao Y, Tudorascu DL, Lopez OL, Cohen AD, Mathis CA, Aizenstein HJ, et al. Amyloid beta Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. *JAMA Neurol*. 2018; 75(1):88–96. <https://doi.org/10.1001/jamaneurol.2017.3029> PMID: 29114732; PubMed Central PMCID: PMC5833487.
115. Berlau DJ, Corrada MM, Robinson JL, Geser F, Arnold SE, Lee VM, et al. Neocortical beta-amyloid area is associated with dementia and APOE in the oldest-old. *Alzheimers Dement*. 2013; 9(6):699–705. <https://doi.org/10.1016/j.jalz.2012.11.011> PMID: 23474043; PubMed Central PMCID: PMC3971646.
116. Kawas CH, Corrada MM. Alzheimer's and dementia in the oldest-old: a century of challenges. *Curr Alzheimer Res*. 2006; 3(5):411–9. <https://doi.org/10.2174/156720506779025233> PMID: 17168640; PubMed Central PMCID: PMC3373256.
117. Sobel E, Louhija J, Sulkava R, Davanipour Z, Kontula K, Miettinen H, et al. Lack of association of apolipoprotein E allele epsilon 4 with late-onset Alzheimer's disease among Finnish centenarians. *Neurology*. 1995; 45(5):903–7. <https://doi.org/10.1212/wnl.45.5.903> PMID: 7746404.
118. Althouse AD. Adjust for Multiple Comparisons? It's Not That Simple. *Ann Thorac Surg*. 2016; 101(5):1644–5. <https://doi.org/10.1016/j.athoracsur.2015.11.024> PMID: 27106412.